Clinical Research

On behalf of a clinical-stage immunotherapy company: NPC secured significant media coverage of the launch of the company’s Phase I/II clinical trials for a vaccine to treat NSCLC, NIH grants and scientific advisory board formation in leading industry publications.

On behalf of a venture capital firm specializing in forming companies based on cutting-edge technologies and breakthrough medical therapies: NPC garnered significant media coverage of the launch of a clinical-stage company focused on the development and commercialization of immunizations to treat a variety of cancers, viral and autoimmune diseases. We later publicized the expansion of the Phase I clinical trial for one of those vaccines.